MedTrace Logo

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

NCT04600089 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-17

No results posted yet for this study

Summary

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Conditions

  • Descending Aortic Dissection
  • Postoperative Pain
  • Thoracoabdominal Aortic Aneurysm

Interventions

DRUG

Saline

Saline infusion

DRUG

Ketamine

Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.

Sponsors & Collaborators

  • Sam Tyagi

    lead OTHER

Principal Investigators

  • Anna Rockich, Pharm D · University of Kentucky

  • Samuel Tyagi, MD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2027-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04600089 on ClinicalTrials.gov